[go: up one dir, main page]

WO2002004480A3 - Connective tissue growth factor-2 - Google Patents

Connective tissue growth factor-2 Download PDF

Info

Publication number
WO2002004480A3
WO2002004480A3 PCT/US2001/021799 US0121799W WO0204480A3 WO 2002004480 A3 WO2002004480 A3 WO 2002004480A3 US 0121799 W US0121799 W US 0121799W WO 0204480 A3 WO0204480 A3 WO 0204480A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
present
growth factor
connective tissue
tissue growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021799
Other languages
French (fr)
Other versions
WO2002004480A2 (en
Inventor
Haodong Li
Mark D Adams
Valerie Calenda
Virginie Fataccioli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Human Genome Sciences Inc
Original Assignee
Transgene SA
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA, Human Genome Sciences Inc filed Critical Transgene SA
Priority to AU2001276868A priority Critical patent/AU2001276868A1/en
Priority to CA002412124A priority patent/CA2412124A1/en
Priority to EP01954638A priority patent/EP1373299A4/en
Publication of WO2002004480A2 publication Critical patent/WO2002004480A2/en
Anticipated expiration legal-status Critical
Publication of WO2002004480A3 publication Critical patent/WO2002004480A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a human CTGH-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
PCT/US2001/021799 2000-07-11 2001-07-11 Connective tissue growth factor-2 Ceased WO2002004480A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001276868A AU2001276868A1 (en) 2000-07-11 2001-07-11 Connective tissue growth factor-2
CA002412124A CA2412124A1 (en) 2000-07-11 2001-07-11 Connective tissue growth factor-2
EP01954638A EP1373299A4 (en) 2000-07-11 2001-07-11 Connective tissue growth factor-2

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21740200P 2000-07-11 2000-07-11
US60/217,402 2000-07-11
US29164201P 2001-05-18 2001-05-18
US60/291,642 2001-05-18

Publications (2)

Publication Number Publication Date
WO2002004480A2 WO2002004480A2 (en) 2002-01-17
WO2002004480A3 true WO2002004480A3 (en) 2003-10-16

Family

ID=26911905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021799 Ceased WO2002004480A2 (en) 2000-07-11 2001-07-11 Connective tissue growth factor-2

Country Status (4)

Country Link
EP (1) EP1373299A4 (en)
AU (1) AU2001276868A1 (en)
CA (1) CA2412124A1 (en)
WO (1) WO2002004480A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991901B2 (en) 2001-01-11 2006-01-31 Curagen Corporation Proteins and nucleic acids encoding same
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
WO2011107590A1 (en) * 2010-03-04 2011-09-09 Wolfgang Poller Cnn1 (cyr61) for prevention and therapy of inflammatory disease
KR102586165B1 (en) * 2019-10-02 2023-10-10 아주대학교산학협력단 Tissue consolidant composition with increased adhesion and binding force to biological tissues and preparing method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US6069006A (en) * 1991-08-30 2000-05-30 University Of South Florida Connective tissue growth factor (CTGF) regulatory nucleic acid sequences
WO2000035939A2 (en) * 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0888452T3 (en) * 1996-03-15 2004-06-14 Munin Corp Human CYR61, an extracellular matrix signaling molecule

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US6069006A (en) * 1991-08-30 2000-05-30 University Of South Florida Connective tissue growth factor (CTGF) regulatory nucleic acid sequences
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
WO2000035939A2 (en) * 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1373299A4 *

Also Published As

Publication number Publication date
AU2001276868A1 (en) 2002-01-21
EP1373299A2 (en) 2004-01-02
EP1373299A4 (en) 2005-01-19
WO2002004480A2 (en) 2002-01-17
CA2412124A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
EP0804562A4 (en) Connective tissue growth factor-2
EP2258383A3 (en) Antigenic peptides derived from telomerase
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
CA2224093A1 (en) Human vascular endothelial growth factor 2
WO1998049300A3 (en) Truncated vegf-related proteins
EP0751992A4 (en) Vascular endothelial growth factor 2
MXPA02006885A (en) Nogo receptormediated blockade of axonal growth.
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
WO2003057158A3 (en) Method of treating apoptosis and compositions thereof
ATE194291T1 (en) NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST RESPIRATORY SYNZYTIAL VIRUS
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
WO2002050277A3 (en) Protein and nucleic acids encoding same
RU2003130638A (en) PROTEIN ASSOCIATED WITH THE DISEASE
WO2001060990A3 (en) Sphingosine kinases
WO2002004480A3 (en) Connective tissue growth factor-2
AR019864A1 (en) PROCESS TO PRODUCE THE ANTIGEN OF TOXOPLASMA SAG1 OR FRAGMENTS OF THE SAME; PROTEIN SAG1 OR FRAGMENTS OF THE SAME EXPRESSED IN SUCH PROCESS; VACCINE COMPOSITIONS THAT INCLUDE SUCH PROTEIN SAG1 OR FRAGMENTS OF THE SAME; USE OF SUCH PROTEIN FOR THE MANUFACTURE OF MEDICINES TO PREVENT
WO1997035976A3 (en) Epidermal differentiation factor
EP0808899A3 (en) Human marco scavenger receptor (HMarcoSR)
EP0990000A4 (en) Connective tissue growth factor-3
MX9707617A (en) Human criptin growth factor.
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders
DE69534452D1 (en) ANTIVIRAL PROTEIN
RU2003136061A (en) METHOD FOR MINI-INVASIVE FIXING OF RIBS FOR MULTIPLE AND FLOTING Fractures
WO2001074897A3 (en) Protein amf-1 to amf-10 and nucleic acids encoding the same
WO2001085903A3 (en) A novel polypeptide- human protein 9 which contains a p5cr characteristic sequence fragment and a polynucleotide encoding the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2412124

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001954638

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001954638

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001954638

Country of ref document: EP